Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 16 years old and up~* Performance Status 70 percent or above~* Patients should have the following diseases:~* Acute myelogenous leukemia (AML)~* Acute lymphocytic leukemia or lymphoblastic lymphoma (ALL)~* Transfusion dependent myelodysplastic syndrome (MDS)~* Non-Hodgkin's Lymphoma (NHL)~* Chronic lymphocytic leukemia (CLL)~* Pulmonary function as measured by forced expiratory volume at one second (FEV1) and/or corrected diffusing capacity of lung for carbon monoxide (DLCO) at 60 percent of predicted or above~* Left ventricular ejection fraction at 45 percent or above~* If the donor-specific HLA antibodies (DSA) are positive, the patient must undergo a desensitization protocol resulting in undetectable DSA prior to day of transplant~Exclusion Criteria:~* Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning (except for hydroxyurea)~* Uncontrolled bacterial, fungal or viral infections at time of study enrollment~* Positive for HIV, human T-cell leukemia virus (HTLV-1) and/or Hepatitis C~* Subjects with signs/symptoms of active central nervous system (CNS) disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- All patients will receive Haploidentical (Type: EXPERIMENTAL): The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. All patients will receive a Haplo-identical stem cell transplantation.~GVHD Prevention Treatment:~Cyclophosphamide 50mg/kg will be administered IV on Day 3 and Day 5 post transplant.~Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant.~Mycophenolate mofetil 15mg/kg will be administered twice a day IV until patient can take it by mouth starting on Day 1 post transplant until 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).